medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-17-48-54medsovet-426Research ArticleКАРДИОЛОГИЯCARDIOLOGYАнтагонисты кальция: от истории создания к современной клинической практикеCalcium antagonists: from history of creation to modern clinical practiceКучминА. Н.KuchminA. N.noemail@neicon.ruЧеркашинД. В.CherkashinD. V.noemail@neicon.ruВоенно-медицинская академия им. С.М. Кирова Минобороны РоссииРоссияMilitary Medical Academy named after S.M. Kirov, Russian Defense MinistryRussian Federation2015301220150174854Copyright © Кучмин А.Н., Черкашин Д.В., 20152015Кучмин А.Н., Черкашин Д.В.Kuchmin A.N., Cherkashin D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/426

В статье обсуждаются проблемы применения антагонистов кальция в клинической практике. С учетом современных рекомендаций определено место антагонистов кальция в лечении основных заболеваний сердечно-сосудистой системы: артериальной гипертензии, ишемической болезни сердца, наджелудочковых аритмий и пр. Приводятся данные клинических исследований, составивших доказательную базу для применения антагонистов кальция. Подчеркивается целесообразность применения антагонистов кальция пролонгированного действия как средств с оптимальным сочетанием эффективности и безопасности. Обсуждаются результаты исследований клинической эффективности лекарственной формы дилтиазем при лечении больных с сердечно-сосудистыми заболеваниями.

The article discusses the problem of using calcium antagonists in clinical practice. Taking into account the current guidelines, the place of calcium antagonists in the treatment of major cardiovascular diseases was defined: hypertension, coronary artery disease, supraventricular arrhythmias, etc. Clinical trials are described which provided the evidence base for the use of calcium antagonists. The feasibility of long-acting calcium channel blockers which represent an optimum combination of efficiency and safety is emphasized. The results of clinical trials evaluating the efficacy of diltiazem for the treatment of patients with cardiovascular diseases are discussed.

дилтиаземантагонисты кальциясердечно-сосудистые заболеванияклиническое применениеcalcium antagonistscardiovascular diseasediltiazemclinical useReferencesHollman A. Plants in cardiology. BMJ, 1992. 40.Hollman A. Plants in cardiology. BMJ, 1992. 40.Rohwedder D, Hacks M. Verapamil. A drug on the threshold of the next decade. Experts in dialoque. Hamburg, Zurich: Wissenschaftsverlag. 1992. 9-18.Rohwedder D, Hacks M. Verapamil. A drug on the threshold of the next decade. Experts in dialoque. Hamburg, Zurich: Wissenschaftsverlag. 1992. 9-18.Sato M, Nagao T, Yamaguchi I et al. Pharmacological studies on a new 1,5-benzothiazepine derivative (CRD-401). Arzneimittelforschung, 1971. 21: 1338-43.Sato M, Nagao T, Yamaguchi I et al. Pharmacological studies on a new 1,5-benzothiazepine derivative (CRD-401). Arzneimittelforschung, 1971. 21: 1338-43.Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J, 1998. 19 (Suppl. F): F14-8.Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J, 1998. 19 (Suppl. F): F14-8.Небиеридзе Д.В., Оганов Р.Г Гиперактивность симпатической нервной системы: клиническое значение и перспективы коррекции. Кардио-васкул. тер. и профилак., 2004. 3 (1): 94-99.Небиеридзе Д.В., Оганов Р.Г Гиперактивность симпатической нервной системы: клиническое значение и перспективы коррекции. Кардио-васкул. тер. и профилак., 2004. 3 (1): 94-99.Kleinbloesem CH, Van Brummelen P, Danhof M et al. Rate of increase in the plasma concentration of Nifedipine as a major determinant of its hemodinamic effects in humans. Clin Pharmacol Ther, 1987. 41: 26-30.Kleinbloesem CH, Van Brummelen P, Danhof M et al. Rate of increase in the plasma concentration of Nifedipine as a major determinant of its hemodinamic effects in humans. Clin Pharmacol Ther, 1987. 41: 26-30.Марцевич С.Ю. АК - эффективность и безопасность применения у больных с сердечно-сосудистыми заболеваниями. Лечащий врач, 1998. (5).Марцевич С.Ю. АК - эффективность и безопасность применения у больных с сердечно-сосудистыми заболеваниями. Лечащий врач, 1998. (5).The HINT research group. Early treatment of unstable angina in the coronary care unit: a randomized, double-blind placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J, 1986. 56: 400-413.The HINT research group. Early treatment of unstable angina in the coronary care unit: a randomized, double-blind placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J, 1986. 56: 400-413.Multicenter Diltiazem Postinfarction Trial Research Group. The effect of Diltiazem on mortality and reinfarction after myocardial infarction. New Engl J Med, 1983. 309: 385-392.Multicenter Diltiazem Postinfarction Trial Research Group. The effect of Diltiazem on mortality and reinfarction after myocardial infarction. New Engl J Med, 1983. 309: 385-392.Psaty B, Heckbert S, Koepsell T et al. The risk of myocardial infarction associated with antihy-pertensive drug therapies. JAMA, 1995. 274: 620-625.Psaty B, Heckbert S, Koepsell T et al. The risk of myocardial infarction associated with antihy-pertensive drug therapies. JAMA, 1995. 274: 620-625.Мясоедова С.Е. Дилтиазем: место в современной терапии сердечно-сосудистых заболеваний. Атмосфера. Новости кардиологии, 2014. 3: 11-15.Мясоедова С.Е. Дилтиазем: место в современной терапии сердечно-сосудистых заболеваний. Атмосфера. Новости кардиологии, 2014. 3: 11-15.Желнов В.В., Петровская Н.В., Комарова И.С., Дворецкий Л.И. Современные пролонгированные АК в клинической практике. Российский медицинский журнал, 2008. 7: 487-492.Желнов В.В., Петровская Н.В., Комарова И.С., Дворецкий Л.И. Современные пролонгированные АК в клинической практике. Российский медицинский журнал, 2008. 7: 487-492.Celis H, Yodfat Y, Thijs L et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract., 1996. 13: 138-143.Celis H, Yodfat Y, Thijs L et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract., 1996. 13: 138-143.Wang JG, Liu G, Wang X et al. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens, 1996. 10: 735-742.Wang JG, Liu G, Wang X et al. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens, 1996. 10: 735-742.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA, 2002. 288: 2981-2997.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA, 2002. 288: 2981-2997.Massie B, Der E, Herman T et al. 24-Hour Efficacy of Once-Daily Diltiazem in Essential Hypertension. Clin. Cardiol., 1992. 15: 365-368.Massie B, Der E, Herman T et al. 24-Hour Efficacy of Once-Daily Diltiazem in Essential Hypertension. Clin. Cardiol., 1992. 15: 365-368.Reams GP, Lau A, Messina C, et al. Efficacy, elec-trocardiographic and renal effects of intravenous diltiazem for essential hypertension. Am. J. Cardiol., 1987. 60(17): 78I-84I.Reams GP, Lau A, Messina C, et al. Efficacy, elec-trocardiographic and renal effects of intravenous diltiazem for essential hypertension. Am. J. Cardiol., 1987. 60(17): 78I-84I.Чазов Е.И., Чазова И.Е. (под ред.). Руководство по артериальной гипертонии. М.: Медиа Медика, 2005. 734.Чазов Е.И., Чазова И.Е. (под ред.). Руководство по артериальной гипертонии. М.: Медиа Медика, 2005. 734.Dalhof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens., 1992. 5: 95-110.Dalhof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens., 1992. 5: 95-110.Watts R, Wing L. A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring. Blood Press, 1998. 7(1): 25-30.Watts R, Wing L. A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring. Blood Press, 1998. 7(1): 25-30.Farbom P, Wahlstrand B, Almgren P. Interaction Between Renal Function and Microalbuminuria for Cardiovascular Risk in Hypertension. The Nordic Diltiazem Study Hypertension, 2008. 52(1): 115-122.Farbom P, Wahlstrand B, Almgren P. Interaction Between Renal Function and Microalbuminuria for Cardiovascular Risk in Hypertension. The Nordic Diltiazem Study Hypertension, 2008. 52(1): 115-122.Sunderrajan S, Reams G, Bauer J. Long-term renal effects of diltiazem in essential hypertension. Am. Heart J., 1987. 114: 383-388.Sunderrajan S, Reams G, Bauer J. Long-term renal effects of diltiazem in essential hypertension. Am. Heart J., 1987. 114: 383-388.Schiffrin B, Pu O, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am. J. Hypertens. 2002; 15(2 Pt 1): 105-110.Schiffrin B, Pu O, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am. J. Hypertens. 2002; 15(2 Pt 1): 105-110.Преображенский Д.В., Стеценко Т.М., Колпакова Е.В. и др. Артериальная гипертензия у лиц пожилого возраста: распространенность, особенности патогенеза и лечения. Consilium medicum, 2005. 7(12).Преображенский Д.В., Стеценко Т.М., Колпакова Е.В. и др. Артериальная гипертензия у лиц пожилого возраста: распространенность, особенности патогенеза и лечения. Consilium medicum, 2005. 7(12).Blood pressure Lowering treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet, 2000. 355: 1955-1964.Blood pressure Lowering treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet, 2000. 355: 1955-1964.Lund-Johansen P, Omvik P. Effect of long-term diltiazem treatment on central haemodynamics and exercise endurance in essential hypertension. Eur. Heart J., 1990. 11: 543-551.Lund-Johansen P, Omvik P. Effect of long-term diltiazem treatment on central haemodynamics and exercise endurance in essential hypertension. Eur. Heart J., 1990. 11: 543-551.Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014. 1(105): 7-94.Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014. 1(105): 7-94.Applegate W, Cohen JD, Wolfson P, et al. Long-term effectiveness of enalapril plus extended-release diltiazem in essential hypertension. Pharmacotherapy, 1997. 17 (1): 107-12.Applegate W, Cohen JD, Wolfson P, et al. Long-term effectiveness of enalapril plus extended-release diltiazem in essential hypertension. Pharmacotherapy, 1997. 17 (1): 107-12.Sever PS, Dahlof B, Poulter NR, et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet, 2005. September 4.Sever PS, Dahlof B, Poulter NR, et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet, 2005. September 4.Hasebe N. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J. Hypertension, 2005. 23(2): 445-453.Hasebe N. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J. Hypertension, 2005. 23(2): 445-453.

The authors declare that there are no conflicts of interest present.